Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Gemcitabine 210-propargyl-10-deazaaminopterin 2tislelizumab 1ontuxizumab 1glofitamab 1enasidenib 1duvelisib 1brincidofovir 1belinostat 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Sensitivity and Specificity 1MLN 8237 1MAC-ST-001 1Folic Acid 1Fentanyl 1Fenretinide 1Commerce 1Bendamustine Hydrochloride 1(N(1),N(12))bis(ethyl)-6,7-dehydrospermine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immunoblastic Lymphadenopathy × MAC-ST-001 × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡